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Genetically modified (GM) soybean (carrying the EPSPS
transgene) is the most common GM food in Korea. In order
to assess whether genetic modification increases the allergenic
risk of soybeans, the allergenicity and IgE-reactive components
of wild-type and GM soybean extracts were compared in
allergic adults who had been sensitized to soybeans. We
enrolled 1,716 adult allergy patients and 40 healthy, non-atopic
controls. Skin prick tests and IgE enzyme linked immuno-
sorbent assays (ELISAs) were performed using wild-type and
GM soybean extracts, along with other common inhaled aller-
gens. The specificities of serum IgE antibodies from allergic
patients and the identities of the IgE-reactive components of
the soybean extracts were compared using ELISA inhibition
testing, 2-dimensional gel electrophoresis, and IgE immuno-
blotting. To evaluate the effects of digestive enzymes and heat
treatment, the soybean extracts were heated or pre- incubated
with or without simulated gastric and intestinal fluids. The IgE
sensitization rates to wild-type and GM soybeans were identi-
cal (3.8% of allergic adults), and circulating IgE antibodies
specific for the two extracts were comparable. The results of
the ELISA inhibition test, SDS-PAGE, and IgE immuno-
blotting showed a similar composition of IgE-binding com-
ponents within the wild-type and GM extracts, which was
confirmed using two-dimensional gel electrophoresis, IgE
immunoblotting, and amino acid sequencing. None of the
subjects had a positive response to purified EPSPS protein in
the skin prick test, ELISA, or IgE immunoblot analysis. These
findings suggest that the IgE sensitization rate to GM soybean
extracts is identical to that of wild-type soybean extracts in
adult allergy patients. In addition, based on both in vivo and
in vitro methods, the allergenicity of wild type and GM soy-
bean extracts was identical.
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INTRODUCTION
Soybeans are a commonly consumed food pro-
duct in Korea, where they are also one of the most
prevalent food allergens. The reported sensitiza-
tion rate to soybeans ranges from 5.6-21%
1 in
pediatric allergy patients with atopic dermatitis
and acute urticaria, compared with 1.8%
2 in the
general Korean population. There is concern about
whether genetic manipulation of crops might
augment the potential allergenicity of these foods
in humans. The FAO/WHO recommends a step-
wise assessment of genetically modified (GM)
foods using both in vivo and in vitro methods
before launching these products in commercial
markets.
3 Soybean has been the most widely cul-
tivated GM crop since 1997, and the major gene that
has been introduced into soybeans is an herbicide
resistance gene called EPSPS (5-enolpyruvylshiki-
mate-3-phosphate synthase). This modified type
of soybean has been in use for more than 10 years
in Korea, but it remains unknown whether GM
soybeans are more allergenic than their non-modi-
fied counterparts. A recent study
4 demonstrated
that GM corn did not increase the risk of allergic
reactions in patients. Another study, using an in
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vitro test, reported that transgenic maize and soya
seemed to be safe in terms of allergenic potential.
5
In this study, we used skin prick testing and IgE
ELISA assays to compare the allergenicity of GM
and wild-type soybean extracts in a larger cohort
of adult allergy patients. We also analyzed the
antibody reactive components of the two extracts




To evaluate the sensitization to GM and wild-
type soybean extracts, 1,716 allergy patients ( 15
years old) and 40 healthy non-atopic subjects were
enrolled by the Department of Allergy and Rheu-
matology, Ajou University School of Medicine,
Suwon, Korea. The GM soybean extract was
Roundup Ready (Monsanto, St. Louis, MO,
USA), into which the 5-enolpyruvylshikimate-3-
phosphate synthase (EPSPS) gene had been incor-
porated. The wild-type soybean extract, called
Daewon, was provided by Daewon Co., Suwon,
South Korea. Between August 2002 and July 2003,
1,716 patients who had been admitted to Ajou
University Hospital for treatment of various
allergic problems were skin tested for reactions to
GM and wild-type soybean extracts and to com-
mon inhaled allergens, including the common
dust mite Dermatophagoides pteronyssinus. Skin
prick tests were performed on the backs of patients,
and responses to 50 common inhalant allergens
and 30 food allergens were tested simultaneously.
The results were read 15 minutes later. The size
of the wheal produced by each allergen and by
the histamine control was expressed in terms of
maximum diameter and vertical height at the
midpoint of the wheal. Skin reactivity was ex-
pressed as the ratio of the allergen-induced wheal
size to the histamine-induced wheal size (A/H).
A/H ratios between 0.1 and 1, with an erythema
diameter < 21 mm were scored as 1+. A/H ratios
between 0.1 and 1, with an erythema diameter >
21 mm, were scored as 2+. A/H ratios ranging
from 1 to 2 were scored as 3+, and A/H ratios
ranging from 2 to 3 were scored as 4+. All A/H
ratios > 3 were scored as 5+. A positive response
was defined as a score greater than 2+ on the skin
prick test. This study was reviewed by the institu-
tional review board at Ajou University Medical
Center, Suwon, Korea.
Preparation of wild-type and GM soybean extracts
GM soybeans were extracted with phosphate-
buffered saline (PBS; pH 7.5, 1:10 w/v), and the
extract was incubated at 4 overnight and then
centrifuged at 12,000-15,000 rpm for 20 minutes.
The supernatant was then dialyzed (6,000 Da
molecular weight cut-off; Spectrum Medical In-
dustries, Houston, TX, USA) against 4 L of PBS for
72 hours at 4 , and the resulting fluid was stored
at -20 until tested. The protein content, as mea-
sured using the Bradford method, was 2.53 mg/
mL. For skin prick tests, the protein was mixed
with sterile glycerin in a ratio of 1:1. The protein
contents of the wild type and GM soybean ex-
tracts were compared by sodium dodecyl poly-
acrylamide gel electrophoresis (SDS-PAGE) under
two conditions: with or without -mercaptoe β -
thanol treatment which showed comparable
results. An antibody specific for the EPSPS anti-
gen was detected only in the GM soybean extract
(Fig. 1). EPSPS antigen and IgG anti-EPSPS anti-
body used in this study were derived from
Monsanto Co., St. Louis, MO, USA.
IgE ELISA assays
The presence of serum IgE specific for the soy-
bean extracts and the EPSPS protein was deter-
mined using ELISA, as described previously.6
Briefly, microtiter plates (Corning, NY, USA) were
coated with 100 L/well of soybean extract (GM or μ
wild-type, 10 g/well) and incubated over μ night at
4 . Each well was washed three times with 0.05%
phosphate-buffered saline-Tween (PBST), and the
remaining binding sites were blocked by incuba-
tion with 10% fetal bovine serum (FBS)-PBS for 1
h at room temperature. Then 50 L of patient or μ
control sera were added to wells at 1:2 dilution
and incubated for 2 hours at room temperature.
The wells were then washed three times with
PBST, and biotin-labeled goat anti-human IgE
antibody (1:1000 v/v dilution; Vector Labs, BurlinEvaluating the Allergic Risk of Genetically Modified Soybean
Yonsei Med J Vol. 47, No. 4, 2006
game, CA, USA) was added to each well and
incubated for 1 hour. The wells were then washed
and incubated with 100 L of streptavidin-per μ -
oxidase (1:1000 v/v; Sigma, St. Louis, MO, USA)
for 30 minutes. The colorimetric reaction was
developed with TMB (3, 3',5, 5'-tetraethylbenzi-
dine) substrate solution for 15 minutes at room
temperature. The reaction was stopped by adding
100 L of 2 N sulfuric acid and the absorbance μ
was read at 450 nm using an automated micro-
plate reader (Benchmark, Bio-Rad, Hercules, CA,
USA). All assays were performed in duplicate.
Positive values were set at three standard deviation
units above the absorbance values of the controls.
ELISA inhibition test
Competitive ELISAs were performed to deter-
mine the specificity of IgE binding to the soybean
extracts and to compare the allergenicity of the
wild-type extracts, GM extracts, and EPSPS. The
sera from four patients with high levels of soy-
bean-specific IgE were pooled and then pre-in-
cubated overnight (4 ) with increasing protein
concentrations (1 to 100 g) of EPSPS, house dust μ
mite, GM soybean extract, or wild-type soybean
extract. The sera were then incubated for 12 hours
in microtiter plates pre-coated with wild-type or
GM soybean extracts. ELISAs were then de-
veloped as described above. As a control, samples
were pre-incubated with PBS (pH 7.5) instead of
EPSPS or soybean extracts. The percentage of inhi-
bition was expressed as (100-[absorbance of the
samples pre-incubated with allergens/absorbance
of the samples pre-incubated with PBS] × 100).
SDS-PAGE and immunoblot analysis
Four to twenty percent gradient SDS-PAGE and
immunoblot analysis were performed under re-
ducing conditions according to methods described
previously.
6 Briefly, the soybean extracts (24 g μ
each) were mixed with sample buffer (31 mmol/L
Tris-HCl, 10% glycerol, 1% SDS, 0.0025% bromo-
phenol blue, 2.5% -mercaptoethanol, pH 6.8) and β
heated in boiling water for 5 minutes. The extracts
were then loaded alongside a standard marker (4
to 250 kDa; Novex, San Diego, CA, USA) onto a
4-20% Tris-glycine gel (Novex, San Diego, CA,
USA) and run at 125 V for 90 minutes. The gel
was fixed and stained with Coomassie brilliant
blue. For immunoblotting, the proteins were trans-
ferred onto a polyvinylidene fluoride membrane
(PVDF; pore size: 0.2 m; Millipore, Bedford, MA, μ
USA) in transfer buffer (25 mmol/L Tris base, 193
mmol/L glycine, 20% methanol) at 200 mA for 90
minutes. The blotted PVDF membrane was cut
into 4-mm widths and the pieces of the membrane
were incubated in 5% skim milk in Tris-buffered
saline (TBS)-Tween (TBST) for 1 hour to block
nonspecific binding. The membranes were then
incubated overnight with either patient or control
sera diluted 1:2 v/v with 3% skim milk TBST.
After a washing step, the membranes were incu-
bated with goat anti-human IgE conjugated with
alkaline phosphatase (Sigma, St. Louis, MO, USA,
Fig. 1. Ten percent SDS-PAGE (A) and IgG immunoblot analysis (B) of wild-type (W) and GM (G) soybean extracts, and
EPSPS (E) protein. Samples were incubated without (1, 3) or with -mercaptoethanol (2, 4). β
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diluted 1:1000 in 3% skim milk TBST). The mem-
branes were developed using BCIP/NBT alkaline
phosphatase substrate (Sigma, St. Louis, MO,
USA).
2D gel electrophoresis
Soybean extracts (40 g) were mixed with rehy μ -
dration buffer (7 mol/L urea, 2 mol/L thiourea,
2% CHAPS, 20 mmol/L DTT, 0.5% IPG buffer, pI
4-7) and applied to an Immobiline(tm) DryStrip
(pI 4-7, Amersham). The gel was incubated at
room temperature overnight and then run at 50 V
for 30 minutes, 500 V for 30 minutes, 1,000 V for
30 minutes, and 5000 V for 90 minutes. The gel
was then incubated in equilibration buffer (1.5
mol/L Tris, 2% SDS, 6 mol/L urea, 30% glycerol)
for 20 minutes at room temperature, after which
the samples were run on a 12% SDS-PAGE with
a 4% stacking gel using the aforementioned
method. 2D gel electrophoresis and transfer to
PVDF membrane were performed in transfer
buffer at 200 mA for 90 min. The membrane was
then blocked by incubation in 5% skim milk-TBST
for 1 hour and then overnight at 4 in pooled
patient sera that had been diluted 1:2 with TBST.
After a wash step, the blots were incubated with
goat anti-human IgE antibody conjugated with
alkaline phosphatase (diluted 1:1000 in 3% skim
milk-TBST). The membrane was then developed
using BCIP/NBT alkaline phosphatase substrate.
N-Terminal amino acid sequencing analysis
To confirm the major allergenic components via
N-terminal sequencing, the 2D gel electropho-
resed proteins were blotted onto a PVDF mem-
brane. The membrane was stained with 0.1%
Coomassie blue in 50% methanol, de-stained in
50% methanol and air-dried. The protein spots
were excised and micro-sequencing was perfor-
med using a Procise 476 A protein sequencer
(Applied Biosystems, Foster, CA, USA).
RESULTS
Allergy skin prick test
The skin prick testing conducted throughout the
full year of the study revealed that 65 (3.8%) of
the 1,716 allergy patients had an A/H score of 2+
in response to the wild-type soybean protein.
Similarly, 66 patients (3.8%) had an A/H score of
2+ in response to the GM soybean protein. Only
one of the allergy patients failed to respond to
both the wild type and GM soybean extracts
(Table 1) and none of the subjects had a positive
response to EPSPS protein.
Specific IgE to soybean and EPSPS
In the subjects who had a positive skin test with
an A/H score of 2+, the prevalence of serum IgE
specific for wild-type and GM soybean extracts
was 80 and 81%, respectively. Of those with an
A/H score of 3+, 4+, or 5+, the prevalence of
serum IgE specific for wild type and GM soybean
proteins was 74 and 66%, 71 and 83%, and 50 and
100%, respectively. The levels of IgE specific for
Table 1. Skin Prick Test and Specific IgE Binding to Wild Type and GM Soybean Extracts in 65 Positive Reactors among
1716 Subjects Tested
Allergen Wild GM
Skin reactivity 2+ 3+ 4+ 5+ 2+ 3+ 4+ 5+
No. 25 31 7 2 28 29 6 3
Specific IgE to
Wild (%) 20 (80) 23 (74) 5 (71) 1 (50) 23 (81) 19 (66) 5 (83) 3 (100)
GM (%) 20 (80) 23 (74) 5 (71) 1 (50) 23 (81) 19 (66) 5 (83) 3 (100)
Wild, wild type soybean extracts; GM, genetically modified soybean extracts; N, number of subjects positive to skin-prick test for
wild-type and GM potatosoybean; Specific IgE, prevalence of serum specific IgE antibody to wild-type and GM potato soybean (number
of subjects with positive serum specific IgE/number of subjects tested in each response group according to the skin prick test using
potato soybean extract).Evaluating the Allergic Risk of Genetically Modified Soybean
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the GM soybean extracts tended to be slightly
higher than those specific for the wild-type
extracts, and the GM extracts elicited a larger
wheal reaction in the skin prick tests (Fig. 2). No
subjects had detectable serum IgE specific for
EPSPS protein.
ELISA inhibition test
ELISA inhibition assays using pooled IgE-posi-
tive sera showed comparable dose-dependent
inhibition by both the wild type and GM soybean
extracts (Fig. 3). The GM soybean extract showed
somewhat greater inhibition than the wild-type
extracts. Minimal inhibition was observed when
the sera were pre-incubated with an extract from
the dust mite allergen D. pteronyssinus, as shown
in Fig. 3A.
SDS-PAGE and IgE- immunoblot analysis
Fig. 4A compares IgE specific for wild type
versus GM soybean extracts in the sera of 14
individuals. The control serum was pooled from
ten patients who had negative responses in the
skin prick test. In the wild-type extracts, 22 pro-
tein bands, which ranged in size from 8 to 119
kDa, were detected using the serum IgE. A 32~
34-kDa band was the most frequently detected,
being observed in 50% of the sera tested. In the
GM soybean extracts, 20 bands, which also ranged
Fig. 2. Soybean-specific serum IgE
binding to both wild-type (open
circles) and GM (closed circles)
extracts by ELISA according to
wild-type soybean skin reactivity.
Horizontal bars indicate mean
values.
Fig. 3. IgE ELISA inhibition re-
sults for wild-type (A) and GM
(B) soybean-coated wells with the
serial addition of EPSPS protein,
wild-type soybean extract, or GM
soybean extract. Significant inhi-
bition was noted for both wild-
type and GM soybean extracts,
while no significant inhibition
was noted with D. pteronyssinus
and EPSPS protein.
A BSang-Ha Kim, et al.
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in size from 8 to 119 kDa, were detected using the
serum antibodies. Similar to the wild-type ex-
tracts, a 33-kDa band was the most prevalent,
detected in 50% of the sera tested (Fig. 4B).
Therefore, the 33-kDa protein was considered to
be the major allergenic protein present in both
wild type and GM soybean extracts. No bands
were detected when sera were tested against
EPSPS protein.
2D gel electrophoresis, IgE immunoblotting, and
N-terminal amino acid sequencing
2D gel electrophoresis and IgE immunoblot an-
Fig. 4. IgE immunoblot analysis of
EPSPS protein (E), wild-type (W)
and GM (G) soybean extracts using
sera from the sensitized patients
(1-14), non-atopic controls (C), anti-
EPSPS antibody (15), and buffer
control (B). Wild-type: Daewon soy-
bean, GM: Roundup Ready soy-
bean (GTS 40- 3-2).
Fig. 5. Two-dimensional gel elec-
trophoresis (A) and IgE immuno-
blot (B) of wild-type and GM
soybean extracts.Evaluating the Allergic Risk of Genetically Modified Soybean
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alysis of pooled sera from patients with high
levels of soybean-specific IgE showed that the
major 33-kDa allergenic protein had a pI of 4.83,
and verified that serum IgE recognized this pro-
tein (Fig. 5).
N-terminal amino acid sequencing of the 33-




This study demonstrates that among allergic
adults in the Korean population, the prevalence of
positive responses to wild type and GM soybean
extracts is equivalent. With the exception of one
individual, all the subjects tested had a positive
response to both extracts. Importantly, no subjects
responded to GM soybean extracts but not to
wild-type extracts, and no subjects responded to
the EPSPS protein alone, suggesting that the
protein product of the genetically introduced gene
was not itself allergenic. The prevalence of serum
IgE specific for soybean proteins, as determined
by ELISA, increased in parallel with increasing
skin reactivity. When the results from ELISA
assays and skin tests were compared, soybean-
specific IgE antibodies were found in 50-100% of
the patients with A/H scores of 2+, with com-
parable antibody titers specific for wild type and
GM extracts. Furthermore, no subjects had de-
tectable EPSPS-specific IgE responses as tested by
ELISA.
According to the Codex Committee on Food
Labeling, the most common allergenic foods
worldwide that are associated with IgE-mediated
reactions include peanuts, soybeans, milk, eggs,
fish, crustaceans, wheat, and tree nuts.
7 As a re-
sult, soybeans are considered one of the causative
agents of food allergies in Korean adults. How-
ever, the results of our study suggest that the
genetic manipulation of soybeans does not in-
crease the allergenicity of soybeans, as allergic
individuals were found to be equally reactive to
wild type and GM soybean extracts.
When the allergenicity of the wild type and GM
soybeans was compared using IgE ELISA inhibi-
tion tests, the GM extract tended to give higher
inhibition percentages than the wild-type extract.
IgE immunoblot analysis using sera from five
patients (2, 8, 9, 10, and 13) showed strong
reactivity to a 33-kDa band from the GM soybean
extract. Similarly, a 32~34-kDa band from the wild
type extract was detected in the same five
patients. 2D gel electrophoresis and IgE blotting
demonstrated that these two bands were identical.
There were no significant differences in soybean-
specific IgE titers between patients that had anti-
body responses specific for the 33-kDa major aller-
gen and those that did not. No significant changes
in IgE binding patterns to another protein (47.5
kDa) were noted, suggesting that the intro-
duction of the gene encoding the EPSPS protein
did not affect the allergenicity of the soybean ex-
tract, either qualitatively or quantitatively. Con-
sistent with this conclusion, none of the patients
had detectable EPSPS-specific IgE antibodies in
their serum. These findings suggest that the
allergenic risk of GM soybeans is identical to that
of wild-type soybeans.
The gapped BLAST and PSI-BLAST programs
were used to search for proteins with an amino
acid sequence similar to the 33-kDa GM soybean
antigen.
8 The search revealed that the 33-kDa
protein is identical to the P34 protein, which was
previously identified as one of the major soybean
allergens and is a member of the papain family of
cysteine proteases.
9 Food allergens commonly ex-
hibit sufficient gastric stability to reach the intesti-
nal mucosa, where absorption and sensitization
can occur. Therefore, important food allergens
may resist digestion in simulated gastric fluid. For
example, soybean -conglycinin is stable in diges β -
tive enzyme for 60 min.
8 In conclusion, we evalu-
ated the allergenicity of GM and wild-type soy-
beans using in vivo and in vitro methods and de-
monstrated that the introduction of the herbicide-
resistance gene EPSPS does not increase allergenic
risk in adult allergy patients. Additional studies
will be needed to evaluate the allergenic risk of
other GM foods in allergy patients before those
foods are released to the consumer market.
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